Anzeige
Mehr »
Dienstag, 12.08.2025 - Börsentäglich über 12.000 News
Desert Gold: Zahlen untermauern das Potential
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLV9 | ISIN: FR0013233012 | Ticker-Symbol: 6IV
Tradegate
11.08.25 | 18:22
2,960 Euro
+0,85 % +0,025
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INVENTIVA SA Chart 1 Jahr
5-Tage-Chart
INVENTIVA SA 5-Tage-Chart
RealtimeGeldBriefZeit
2,8902,96511.08.
2,9052,96011.08.

Aktuelle News zur INVENTIVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INVENTIVA Aktie jetzt für 0€ handeln
MoINVENTIVA: Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference249Daix) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH")...
► Artikel lesen
31.07.INVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux323Daix (France), New York (New York, United States), July 31, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the...
► Artikel lesen
29.07.INVENTIVA: Inventiva Reports Preliminary 2025 First-Half Financial Information994Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United...
► Artikel lesen
09.07.Inventiva beruft neue Führungskräfte für Forschung & Entwicklung und regulatorische Angelegenheiten6
09.07.Inventiva appoints new R&D president and regulatory affairs executive2
09.07.INVENTIVA: Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance347Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President...
► Artikel lesen
09.07.Inventiva Receives $10 Mln Milestone Payment From CTTQ For MASH Drug Development2
07.07.Inventiva S.A. - 6-K, Report of foreign issuer-
07.07.INVENTIVA: Inventiva receives $10 million milestone payment from CTTQ735Daix (France), New York City (New York, United States), July 7, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on...
► Artikel lesen
02.07.INVENTIVA: Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease358Analysis of liver sinusoidal endothelial cells ("LSEC") from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and...
► Artikel lesen
10.06.INVENTIVA: Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors527Daix (France), New York City (New York, United States), June 10, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused...
► Artikel lesen
27.05.INVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference349Daix (France), New York City (New York, United States), May 27, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on...
► Artikel lesen
23.05.Inventiva S.A. reports Q1 results1
23.05.INVENTIVA: Inventiva reports 2025 First Quarter Financial Information382Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical...
► Artikel lesen
23.05.INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025195Daix (France), New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development...
► Artikel lesen
22.05.Inventiva S.A. - 6-K, Report of foreign issuer2
22.05.Inventiva sets share repurchase program terms post-meeting5
22.05.INVENTIVA: Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux274Daix, May 22, 2025 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), the purpose of this description is to present the objectives...
► Artikel lesen
05.05.Inventiva secures €116 million second tranche of structured financing of up to €348 million2
05.05.INVENTIVA: Inventiva secures the €116 million second tranche of its structured financing of up to €348 million397Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United...
► Artikel lesen
Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1